ES2905208T3 - Medios y métodos para la estadificación, tipificación y tratamiento de una enfermedad cancerosa - Google Patents

Medios y métodos para la estadificación, tipificación y tratamiento de una enfermedad cancerosa Download PDF

Info

Publication number
ES2905208T3
ES2905208T3 ES16152883T ES16152883T ES2905208T3 ES 2905208 T3 ES2905208 T3 ES 2905208T3 ES 16152883 T ES16152883 T ES 16152883T ES 16152883 T ES16152883 T ES 16152883T ES 2905208 T3 ES2905208 T3 ES 2905208T3
Authority
ES
Spain
Prior art keywords
dcc
cancer
somatic
alterations
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16152883T
Other languages
English (en)
Spanish (es)
Inventor
Christoph Klein
Sebastian Scheitler
Melanie Werner-Klein
Martin Hoffmann
Isabelle Hodak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Regensburg
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung eV
Original Assignee
University of Regensburg
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Regensburg, Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung eV filed Critical University of Regensburg
Application granted granted Critical
Publication of ES2905208T3 publication Critical patent/ES2905208T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES16152883T 2016-01-27 2016-01-27 Medios y métodos para la estadificación, tipificación y tratamiento de una enfermedad cancerosa Active ES2905208T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (1)

Publication Number Publication Date
ES2905208T3 true ES2905208T3 (es) 2022-04-07

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16152883T Active ES2905208T3 (es) 2016-01-27 2016-01-27 Medios y métodos para la estadificación, tipificación y tratamiento de una enfermedad cancerosa

Country Status (9)

Country Link
US (1) US11702701B2 (cg-RX-API-DMAC10.html)
EP (2) EP3199641B1 (cg-RX-API-DMAC10.html)
JP (1) JP2019508032A (cg-RX-API-DMAC10.html)
CN (1) CN108770360B (cg-RX-API-DMAC10.html)
AU (1) AU2017211976B2 (cg-RX-API-DMAC10.html)
CA (1) CA3012404A1 (cg-RX-API-DMAC10.html)
ES (1) ES2905208T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201805990XA (cg-RX-API-DMAC10.html)
WO (1) WO2017129753A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1109938T3 (da) 1998-09-18 2002-05-27 Micromet Ag DNA-amplificering af en enkelt celle
AU2002216009A1 (en) * 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
ITRM20110149A1 (it) * 2011-03-25 2012-09-26 Massimo Zollo Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione.
WO2013009632A2 (en) * 2011-07-08 2013-01-17 The University Of Utah Research Foundation Methods of detecting hereditary cancer predisposition
JP2015500035A (ja) * 2011-12-10 2015-01-05 アボツト・モレキユラー・インコーポレイテツド 悪性黒色腫の診断および悪性黒色腫の転移の予後予測のための物質および方法
EP3033150A4 (en) * 2013-08-13 2017-06-28 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
WO2015118077A1 (en) 2014-02-05 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Error-free sequencing of dna

Also Published As

Publication number Publication date
CA3012404A1 (en) 2017-08-03
AU2017211976A1 (en) 2018-08-02
EP3199641A1 (en) 2017-08-02
EP3408411A1 (en) 2018-12-05
JP2019508032A (ja) 2019-03-28
US11702701B2 (en) 2023-07-18
SG11201805990XA (en) 2018-08-30
US20190062845A1 (en) 2019-02-28
KR20180102674A (ko) 2018-09-17
AU2017211976B2 (en) 2022-09-22
EP3199641B1 (en) 2021-09-29
WO2017129753A8 (en) 2017-10-19
WO2017129753A1 (en) 2017-08-03
CN108770360B (zh) 2022-06-14
CN108770360A (zh) 2018-11-06

Similar Documents

Publication Publication Date Title
Perrone et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
Hodgkinson et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Onozato et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers
Reimers et al. Biomarkers in precision therapy in colorectal cancer
Bardelli et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
US9441277B2 (en) Compositions and methods for detecting cancer metastasis
Kin et al. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis
Ueno et al. Impact of age on epidermal growth factor receptor mutation in lung cancer
Draht et al. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients
Sterlacci et al. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas
Tong et al. SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis
Lurje et al. Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma
Wang et al. Molecular subtyping in colorectal cancer: A bridge to personalized therapy
Gasparini et al. Prognostic determinants in epithelioid sarcoma
Keller et al. Molecular pathogenesis of penile squamous cell carcinoma: current understanding and potential treatment implications
CN114502745A (zh) 利用脱氧核糖核酸甲基化突变的抗癌免疫治疗反应性预测方法
Vasseur et al. Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression
EP3199641B1 (en) Means and methods for staging, typing and treating a cancerous disease
Kim et al. Deletion in HSP110 T17: Correlation with wild-type HSP110 expression and prognostic significance in microsatellite-unstable advanced gastric cancers
EP3126520B1 (en) Amg-337 for use in the treatment of cancers having a met amplification
TWI680297B (zh) 評估罹癌個體是否適用抗癌藥物的方法
Egeli et al. Impact of 3′ UTR variation patterns of the KRAS gene on the aggressiveness of pancreatobiliary tumors with the KRAS G13D mutation in a Turkish population
El Founini et al. Lung cancer in Morocco: EGFR and PIK3CA mutations as therapeutic targets and the lack of HER2 mutations
JP5713306B2 (ja) ガンのリンパ節転移抑制剤
Tinsley Deregulated Pathways in Metachronous Colorectal Cancer Peritoneal Metastases